DHEA & the Adrenal Decline Clock:
What Happens After 30

What DHEA Actually Is — and Why It Matters

DHEA (dehydroepiandrosterone) and its sulfated form DHEA-S are produced primarily by the adrenal zona reticularis — the innermost cortical zone of your adrenal glands, sitting just above your kidneys. Smaller quantities come from the gonads and, importantly, from local synthesis in peripheral tissues including the brain, skin, breast, and prostate.

Circulating DHEA-S functions as a reservoir. Peripheral tissues convert it on-demand into biologically active androgens (testosterone, androstenediol) and estrogens (estrone, estradiol) via local enzymatic machinery. This tissue-specific hormone synthesis — operating independently of the gonads — is called intracrinology, a concept pioneered by endocrinologist Fernand Labrie at Laval University. It means that even in postmenopausal women or men with lower testicular output, peripheral DHEA conversion remains a meaningful source of sex steroid activity at the tissue level.

This distinction matters clinically. Blood testosterone or estrogen levels do not capture what is happening inside tissues. A woman's breast or vaginal tissue may be converting DHEA into active estrogens even when serum estrogen reads as undetectable. This intracrine action explains much of DHEA's tissue-specific effects and underlies why vaginal DHEA (Prasterone) received FDA approval without significantly elevating systemic hormone levels.

The Adrenopause Curve: Mapping the Decline

Cortisol — the other major adrenal steroid — is preserved with age. DHEA-S is not. This selective collapse of DHEA-S production, with cortisol remaining relatively intact, creates a profoundly altered cortisol:DHEA ratio in older adults. Since DHEA exerts many anti-glucocorticoid effects (opposing cortisol's catabolic, immunosuppressive, and pro-inflammatory actions), this ratio shift may amplify the damaging downstream effects of cortisol on muscle, bone, immune function, and the hippocampus.

The decline begins insidiously in the early 30s, accelerates through midlife, and reaches a nadir in advanced old age. Men tend to start from a higher baseline; women show a sharper relative drop at menopause. The variation between individuals is substantial — a 65-year-old may have DHEA-S levels anywhere from 20 to 250 mcg/dL, depending on genetics, lifestyle, and health status.

DHEA-S Reference Ranges by Age

Reference ranges adapted from standard laboratory norms. Individual variation is significant. Testing in a morning fasted state provides the most consistent readings.

DHEA-S as a Biological Age Biomarker

Population studies have repeatedly identified DHEA-S as a correlate of biological aging and longevity. The MacArthur Studies of Successful Aging found that higher DHEA-S at baseline predicted better physical and cognitive function in older adults at follow-up. A landmark analysis of the Rancho Bernardo cohort (Barrett-Connor) found that men with higher DHEA-S had significantly lower all-cause and cardiovascular mortality over 19 years of follow-up.

Low DHEA-S has been associated — across multiple independent cohorts — with:

• Cardiovascular disease — endothelial dysfunction, atherosclerosis progression, and higher cardiac event rates
• Cognitive decline and dementia — DHEA receptors exist in hippocampal tissue; DHEA has neuroprotective and neurogenic effects in animal models
• Physical frailty — reduced grip strength, slower gait speed, sarcopenia
• Depression and dysthymia — DHEA modulates GABA-A and NMDA receptors; it has measurable antidepressant activity
• Insulin resistance and metabolic syndrome — DHEA improves insulin sensitivity in both animal models and some human trials
• All-cause mortality — independent predictor in multiple prospective studies, even after adjusting for confounders

The causal direction remains debated. Does low DHEA-S cause poor health outcomes, or does poor health suppress DHEA-S production? Almost certainly both. DHEA-S is simultaneously a driver and a read-out of biological aging — which is exactly what makes it a clinically useful biomarker.

What the Clinical Evidence Actually Shows

The DHEA supplementation literature is large, sometimes contradictory, and requires careful parsing. Here is what the highest-quality evidence supports:

Vaginal Atrophy and Sexual Function — FDA Approval

Fernand Labrie's decades of intracrinology research culminated in the FDA approval of Prasterone (Intrarosa) — vaginal DHEA — for dyspareunia (painful sex) due to menopause-associated vulvovaginal atrophy. The pivotal Phase 3 trials showed significant improvements in vaginal tissue, lubrication, and sexual function with 0.5% DHEA suppositories inserted nightly. Crucially, systemic hormone levels (estradiol, testosterone) remained within normal postmenopausal ranges, demonstrating the intracrine mechanism in action.

Bone Density — The Jankowski and Nair Evidence

Jankowski et al. (2006) randomized older women to 50 mg/day oral DHEA for 12 months and observed significant increases in lumbar spine bone mineral density versus placebo — with no significant change in hip BMD. The landmark Nair et al. (2006) NEJM study from the Mayo Clinic gave 50 mg/day DHEA to elderly men and women for two years. Results: older women showed significant improvements in bone density and muscle strength. Men showed less consistent benefit. This sex-specific response is attributed to differences in how DHEA is peripherally converted in male versus female tissue.

Mood and Depression — The Wolkowitz Data

Owen Wolkowitz at UCSF conducted multiple trials of DHEA in patients with major depression, finding significant antidepressant effects particularly in those with low baseline DHEA-S levels. A NIH-funded crossover trial confirmed that DHEA produced robust improvements in depressive and anxiety symptoms in patients with midlife-onset dysthymia. The effect size was clinically meaningful — comparable to standard antidepressants in this population. In contrast, trials in non-depressed or non-deficient populations show far weaker or null effects.

Cognition — Mixed Picture

The Barrett-Connor cohort data, while showing survival benefits in men, did not demonstrate significant cognitive preservation with higher DHEA-S in a general healthy population. RCTs of DHEA supplementation on cognition in cognitively normal older adults have been largely negative. The picture is different in states of frank deficiency (Addison's disease, hypopituitarism) — where DHEA replacement consistently improves well-being, mood, and sometimes cognitive performance. The lesson: DHEA supplementation appears most beneficial when correcting a genuine deficiency, not when added on top of already-adequate levels.

Body Composition — Modest Effects

Multiple trials have shown minor improvements in fat mass and lean mass at doses of 50–100 mg/day, particularly in older adults. The effects are modest and not consistently replicated. DHEA is not a performance-enhancing drug in any meaningful clinical sense, and it is banned by WADA in competitive sport precisely because of its androgen precursor status — not because the anabolic effects are large.

Risks, Side Effects, and Who Should Avoid It

DHEA is sold over-the-counter in the United States as a dietary supplement. This regulatory status does not mean it is without risk. As an androgen precursor, oral DHEA can produce androgenic side effects — acne, oily skin, hair thinning (androgenic alopecia), and increased facial hair in women — particularly at doses above 25–50 mg/day or in individuals who are efficient converters.

Estrogen conversion is a consideration for anyone with a history of hormone-sensitive cancers (breast, endometrial, prostate). While intravaginal DHEA largely bypasses systemic estrogen elevation, oral DHEA does raise circulating estrogens in women — a factor requiring individualized risk assessment.

The appropriate starting dose in most research protocols is 25 mg/day for women and 50 mg/day for men, taken in the morning with food to mirror the natural diurnal cortisol-DHEA rhythm. The goal is not to maximize DHEA-S but to restore it to the youthful-end of the age-adjusted reference range.

Frequently Asked Questions

Is DHEA safe to buy and take without a prescription?

In the United States, oral DHEA is legally sold as an over-the-counter dietary supplement. However, legal availability does not equal safety for everyone. People with hormone-sensitive cancers, PCOS, or liver conditions should not use it without physician oversight. In many other countries — including the UK, Canada, and Australia — DHEA is classified as a prescription drug.

How long does it take to see results from DHEA supplementation?

DHEA-S levels normalize within 4–8 weeks of consistent supplementation. Downstream effects — on bone markers, mood, body composition — typically require 3–6 months of consistent use to become measurable. Vaginal tissue response (for intravaginal DHEA) shows improvement within 6–12 weeks in clinical trials.

Can I raise my DHEA without supplements?

Meaningful lifestyle-driven increases in DHEA-S are achievable but limited. The most reliably supported interventions are: consistent high-quality sleep (7–9 hours with adequate deep sleep stages), HIIT exercise 2–3× weekly, and reducing chronic psychological stress. These approaches improve the cortisol:DHEA ratio even when absolute DHEA-S rises only modestly — which may be where much of the health benefit lies.

Why does the evidence for DHEA seem inconsistent across studies?

Three factors drive heterogeneity in the DHEA literature: (1) baseline levels — studies enrolling deficient participants show effects; those enrolling replete participants do not; (2) dose — 25–50 mg/day is well-studied; doses above 100 mg/day carry more risk with marginal added benefit; (3) sex — women's peripheral tissue is more responsive to DHEA aromatization, producing more consistent effects on bone, mood, and vaginal tissue than is seen in men at equivalent doses.